WASHINGTON (dpa-AFX) - AbbVie (ABBV) and FutureGen Biopharmaceutical Beijing Co. announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of IBD currently in preclinical development. AbbVie will receive an exclusive global license to develop, manufacture and commercialize FG-M701. FutureGen will receive $150 million in upfront and near-term milestone payments and will be eligible to receive up to an additional $1.56 billion in milestones, as well as tiered royalties up to low-double digits on net sales.
FutureGen Biopharmaceutical is a biopharmaceutical company committed to providing biologics for patients with cancer, immune diseases and other diseases.
For More Such Health News, visit rttnews.com.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2024 AFX News
